December 6-8, 2026
Hyatt Regency Austin
Austin, Texas

Advance Registration Deadline: Tuesday, October 27, 2026 1 p.m. ET

CONFERENCE COCHAIRS

Richard S. Finn, UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, New York
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

Liver cancer remains a major global health challenge and is now among the leading causes of cancer-related mortality worldwide. By 2026, liver cancer is estimated to affect over one million individuals annually, with incidence continuing to rise, particularly in high-risk and underserved populations. Despite significant advances in our understanding of disease biology and therapeutic development, most patients with liver cancer still present at advanced stages, limiting curative options and contributing to suboptimal outcomes.

This second program brings together international leaders in liver cancer research and clinical care to address critical gaps in knowledge and management across disease subtypes. The meeting will explore the molecular pathogenesis and risk factors driving hepatocellular carcinoma (HCC), the evolving role of immunotherapies in early, intermediate, and advanced HCC, and emerging molecular and immune-based treatment strategies. Dedicated sessions will also focus on the molecular pathogenesis and therapies for cholangiocarcinoma, as well as health disparities, pediatric liver tumors, and the patient advocacy perspective.

Across plenary sessions, speakers will examine the contributions of the tumor microenvironment, immune modulation, and the microbiome to liver cancer development and progression. Additional emphasis will be placed on mechanisms of action of current therapies, predictive biomarkers, innovative clinical trial design, liquid biopsy approaches, and the scientific rationale for future therapeutic combinations.

Join the conversation with basic scientists, physician-scientists, and industry professionals, all united by a shared goal: advancing research and improving outcomes for patients facing this aggressive and complex disease.

Please Note: All presentations at this event represent the opinions of the presenter and do not represent the position or the opinion of the AACR or its members.